Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10821499
Filing Date		2007-10-25
First Named Inventor Webb		et al.
Art Unit		3626
Examiner Name		
Attorney Docket Number		P0011232.00

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	)ate	Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relev Figures Appear		
	1	6250309		2001-06	i-26	Krichen et al.					
If you wish	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	of cited Decument		Releva	Columns, int Passaç s Appear	Lines where ges or Relev	) /ant
	1										
If you wish	h to a	dd additional U.S. Publ		,				d button	Add		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	,	Kind Code4	Publication Date	Name of Patente Applicant of cited Document	or '	Pages,Col	or Relevant	т
	1	WO01387	wo		A	2002-01-03	Medironic Inc.				_
	2	WO0193104	wo		A	2001-12-06	12 Technologies, In	c.			С
16	h to a	l dd additional Foreign P	atont Do	cument	citation	information n	L lassa click the Add	hutton	Add		_

#### 

Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published,	Ţ5
	1	HUTTEN H. et al., "Der Herzschniffmacher Als Bruecke Zurn Kardislen Telemonstoring" Biomedizinische Technik, Fachvertag Scheie Und Schoen Gmöht. Berin De, vol.41, no. 6, June 1996 pp. 158-163.	
	2	CHOI J. et al., "Development of an Online Database System for Remote Monitoring of Artificial Heart Patient", Information Technology Applications in Biomedicine, 2003. 4th International IEEE EMBS Special Topic Conference on 24-26 April 2003, Piscataway, NJ, USA, IEEE, 24 April 2003, pp. 59-61.	
If you wis	h to a	d additional non-patent literature document citation information please click the Add button Add	
		EXAMINER SIGNATURE	

\*EXAMINER: nitial if reference considered, whether or not clation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

1 See Kind Codes of USPTO Patient Documents at www.LISETD.CODU or MPEP 901.64. <sup>2</sup> Either office that issued the document, by the howleter code (WIPO Standard ST3.) <sup>2</sup> For Jupanese patient concurrent, by management of the Deprover must proceed the serial number of the patient concurrent, <sup>2</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>3</sup> Applicant is to place a check mark here if English Impropriate Parisations in attached.

Examiner Signature

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 GFR 1.99)

Application Number		10821499
Filing Date		2007-10-25
First Named Inventor	Webb	et al.
Art Unit		3626
Examiner Name		
Attorney Docket Number		P0011232 00

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.9	to make the	appropriate	selection(s):
---------------	----------	---------	-------------	-------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Daniel G. Chapik/	Date (YYYY-MM-DD)	2007-10-25
Name/Print	Daniel G. Chapik	Registration Number	43.424

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2231-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2231-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.